The estimated Net Worth of Capital Group, Llcepq Llc A... is at least $2.15 millió dollars as of 16 November 2021. Capital A owns over 11,135 units of Applied Molecular Transport stock worth over $2,151,598 and over the last 4 years Capital sold AMTI stock worth over $0.
Sign up
Capital A AMTI stock SEC Form 4 insiders trading
Capital has made over 2 trades of the Applied Molecular Transport stock since 2020, according to the Form 4 filled with the SEC. Most recently Capital bought 11,135 units of AMTI stock worth $249,981 on 16 November 2021.
The largest trade Capital's ever made was buying 2,720,000 units of Applied Molecular Transport stock on 9 June 2020 worth over $38,080,000. On average, Capital trades about 1,365,568 units every 263 days since 2020. As of 16 November 2021 Capital still owns at least 8,275,375 units of Applied Molecular Transport stock.
You can see the complete history of Capital A stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Applied Molecular Transport
Over the last 4 years, insiders at Applied Molecular Transport have traded over $9,673,149 worth of Applied Molecular Transport stock and bought 3,091,278 units worth $40,384,206 . The most active insiders traders include Capital Group, Llcepq Llc A..., Helen Susan Kim és Tahir Ph.D. Mahmood. On average, Applied Molecular Transport executives and independent directors trade stock every 24 days with the average trade being worth of $26,155. The most recent stock trade was executed by Tahir Ph.D. Mahmood on 22 November 2023, trading 286,320 units of AMTI stock currently worth $45,811.
What does Applied Molecular Transport do?
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
What does Applied Molecular Transport's logo look like?
Complete history of Capital A stock trades at Applied Molecular Transport
Applied Molecular Transport executives and stock owners
Applied Molecular Transport executives and other stock owners filed with the SEC include:
-
Dr. Tahir Mahmood Ph.D.,
Co-Founder, CEO & Director -
Dr. Randall Mrsny Ph.D.,
Co-Founder, Chief Scientific Officer & Director -
Elizabeth P. Bhatt M.B.A.,
Chief Bus. & Strategy Officer -
Shawn M. Cross,
Chief Financial Officer -
Graham K. Cooper,
Exec. Chairman -
Dr. Andy Whitney Ph.D.,
VP and Head of Preclinical Devel. & Translational Science -
Earl M. Douglas,
Exec. VP & Gen. Counsel -
Andrew H. Chang,
Head of Investor Relations & Corp. Communications -
Douglas A. Rich M.B.A., M.B.A,
Chief Technical Officer -
Brandon Hants,
Sr. VP of Fin. & Bus. Operations and Principal Accounting Officer -
John W Smither,
Director -
Capital Group, Llc Boeding ...,
-
Helen Susan Kim,
Director -
David Lamond,
Director -
Fund V, Lp Founders Fund V ...,
-
Tahir Ph.D. Mahmood,
Director -
Bittoo Kanwar,
Chief Medical Officer -
Aaron Van Devender,
Director -
Capital Group, Llcepq Llc A...,
-
Capital Group, Llcepq Llc A...,
-
Douglas A. Rich,
Chief Technical Officer -
Elizabeth Bhatt,
Chief Bus. & Strategy Officer -
Graham K Cooper,
Director -
Holly Caren Schachner,
Director -
Charlene A. Banard,
Director -
Shawn Cross,
CEO & Chair of the Board -
Brandon Hants,
CFO